Drug Trial Radar · NCT04952064
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Sep 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jul 28, 2021
Primary completion
Jul 18, 2022
Study completion Jul 18, 2022
Sponsor
- Lead sponsor
- General Hospital of Shenyang Military RegionAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Third Xiangya Hospital of Central South University
- First posted
- Jul 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of higher doses of monosialoganglioside GM1 injection in the treatment of patients with acute ischemic stroke.
Conditions
- Stroke, Ischemic
Interventions
Monosialoganglioside GM1Drug
Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of modified Rankin Scale (mRS) 0-2Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Hospital of ShenYang Military Region
Shenyang, Liaoning, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.